| Aug 14 |
We're Hopeful That Erasca (NASDAQ:ERAS) Will Use Its Cash Wisely
|
| Aug 13 |
Erasca GAAP EPS of -$0.29
|
| Aug 12 |
Erasca Reports Second Quarter 2024 Business Updates and Financial Results
|
| Jun 18 |
Erasca kicks off Phase III trial for naporafenib combo therapy in melanoma
|
| Jun 18 |
Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma
|
| Jun 4 |
Should You Buy Erasca, Inc. (ERAS) After Golden Cross?
|
| May 29 |
Erasca to Present at Upcoming Investor Conferences in June
|
| May 23 |
Independent Director of Erasca Picks Up 14% More Stock
|
| May 21 |
Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
|
